Therefore, Matsuzaki and colleagues hypothesised that preventing linker phosphorylation would shift malignant- to tumour-suppressive TGFβ signalling, providing a novel therapeutic approach for advanced cancers [13, 15]. Here, TGFB1 is linked to cancer.